Compare Vanguard Value Index Fund ETF (VTV) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Value Index Fund ETF vs Zimmer Biomet Holdings Inc — how do they compare? Vanguard Value Index Fund ETF trades at $226.38, while Zimmer Biomet Holdings Inc trades at $96.44 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while Vanguard Value Index Fund ETF pays none, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| VTV | ZBH | |
|---|---|---|
52-Week High | $225.35 | $107.71 |
52-Week Low | $179.43 | $79.58 |
Market Cap | — | $18.55B |
Sector | — | Health |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vanguard Value ETF (VTV) trades at $226.09, up 0.48% with bullish technical signals from moving averages. The ETF focuses on large-cap value stocks and has gained attention for outperforming growth counterparts in 2026, with one Vanguard deep-value fund reportedly up 22% year-to-date according to 247 Wallst on August 10, 2026. Recent institutional activity shows mixed positioning with some firms reducing stakes while others increased holdings.
The outlook remains positive as value strategies gain traction amid tech sector volatility. Key risks include concentration in value stocks and market rotation patterns. Institutional interest persists despite some profit-taking, suggesting continued confidence in the value premium.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
